Evommune Announces Closing of its Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares November 10, 2025
TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027 November 10, 2025
Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results November 3, 2025
Italian biotech AAVantgarde adds $141M series B to fund retinal disease gene therapy trials November 3, 2025
